Janus Henderson Group PLC Sells 2,290 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janus Henderson Group PLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 98,134 shares of the biopharmaceutical company's stock after selling 2,290 shares during the quarter. Janus Henderson Group PLC owned 0.09% of Regeneron Pharmaceuticals worth $103,180,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. International Assets Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock valued at $926,078,000 after acquiring an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company's stock worth $707,759,000 after buying an additional 11,499 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Regeneron Pharmaceuticals by 12.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company's stock worth $567,864,000 after buying an additional 59,769 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Regeneron Pharmaceuticals by 23.8% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock worth $525,804,000 after buying an additional 96,266 shares during the last quarter. Finally, TD Asset Management Inc grew its stake in shares of Regeneron Pharmaceuticals by 30.4% during the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock worth $369,484,000 after buying an additional 82,034 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ:REGN traded up $13.64 during midday trading on Thursday, hitting $767.90. 779,037 shares of the company's stock were exchanged, compared to its average volume of 546,782. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a 50 day moving average price of $882.14 and a 200-day moving average price of $1,013.01. The company has a market cap of $84.38 billion, a PE ratio of 19.00, a price-to-earnings-growth ratio of 2.89 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, October 22nd. Oppenheimer cut their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Royal Bank of Canada cut their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,107.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.